A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins
about
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived XenograftsHuman papillomavirus induced transformation in cervical and head and neck cancersInfluence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenograftsFGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell CancersGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRAn Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentPhase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesPatient-derived xenograft models: an emerging platform for translational cancer researchA comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.Long term storage of dry versus frozen RNA for next generation molecular studies.TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation.An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.Xenograft assessment of predictive biomarkers for standard head and neck cancer therapiesThe role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses.XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancerDNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation.Radiation dose uncertainty and correction for a mouse orthotopic and xenograft irradiation model.Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer.A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerPatient-derived xenograft (PDX) tumors increase growth rate with time.Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.Patient-derived xenografts as tools in pharmaceutical development.Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line.PI3K is required for both basal and LPA-induced DNA synthesis in oral carcinoma cells.Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.Barriers to generating PDX models of HPV-related head and neck cancer.Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.[Gene expression analyses and their possible clinical benefit in head and neck cancer].A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.Systematic module approach identifies altered genes and pathways in four types of ovarian cancer.A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.
P2860
Q26772895-F62242E5-E985-4E3E-94CF-ED3401E27BBEQ27003141-46BCC7C9-52AA-4688-A2B9-58DCAFB5332FQ27321370-DDB4E05D-8DEA-4AD8-B858-6B07A04D5602Q27853171-E10244DF-346A-45B9-9999-37E3E9673692Q28086993-8B90834C-2B50-47EF-8990-E22548987896Q28265615-BC37CF0A-163C-4267-AD26-942FB8F6B600Q33607965-13685343-0565-4454-BF16-D682314DD967Q34159739-491649AC-DB6B-444B-9A42-8662B4FEAF0CQ34205518-B03F91B6-42C9-4718-9307-C7A610DF2536Q34458117-24D8BE5D-1FC7-46E3-A5C3-A0C86282916FQ34620099-61FF4B71-49AF-4648-B44C-DE96456C324EQ35214530-33DD8B67-396E-4110-82D8-DCA5E3445C42Q35403674-3EBEA8D4-4D8C-4248-8FB9-37C3B6423CF9Q35562945-837CA29B-C2CF-43CA-933B-098EFE60F816Q35577672-F6207878-196B-4F0E-89DA-707AE89599FDQ35602135-E8D634AC-A435-4D09-BD69-FA2A04F9083FQ35838573-38485B13-2855-4889-826E-AFBDCA417E6DQ36185583-C490E60E-D0F9-4B78-96E1-AFC2D76DAD1AQ36349712-90BA9E50-5D81-4D89-98F4-ECD27B06092FQ36571756-16CF8F4D-1818-4E7F-B0C9-414A66C00A46Q36633405-0AEED864-67B1-4C60-B3DE-256F36637939Q36872593-86260AE9-7C59-4CF6-9019-92AC7E057D1BQ36946697-B6DA0491-FCAD-443D-B6A2-4FA9F1460986Q37132630-944F266F-28DC-4BAF-9E20-D3F233A8E060Q37228078-871EFC6E-E4A1-40CD-AC4C-450E95292361Q38161944-0BC6DAE8-BD37-4034-849E-B15BC9C75528Q38689944-CE29135C-5878-4EAB-8DD4-944F42B64FC1Q38732336-2DF97976-BAF8-4B71-8131-0E22E49832BEQ38765553-541DDEEF-E1D3-4D2B-8C53-FDDE689A43D0Q38817086-757FBF00-13C4-48A6-A300-D1D7EE5469F2Q38818008-EEB1C0B6-705A-42D4-9462-9AC2E82344DAQ40179397-F595CBD0-8F9C-4D7A-8FB0-101959F94E90Q40578862-86135149-3C78-4B65-BC66-93847EA6F9A5Q40950277-E2755653-15C1-4207-B780-3B6CEC287D94Q41658087-7F65BEE3-282C-4BA9-8D0C-7F825123A992Q41990579-07C450C1-5AA9-449E-83A9-AEEF40660D26Q45007278-7CB4AEC5-0B7B-4760-AAE0-4C19EBBD2F56Q45068320-A6ACAA9F-67FF-487F-A38A-E1703A761630Q47117489-6531EFB9-368F-4AED-B091-BD694AA70361Q47137989-45580325-A00F-4F27-9D85-94002A802320
P2860
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A patient tumor transplant mod ...... tics in defined molecular bins
@en
A patient tumor transplant mod ...... ics in defined molecular bins.
@nl
type
label
A patient tumor transplant mod ...... tics in defined molecular bins
@en
A patient tumor transplant mod ...... ics in defined molecular bins.
@nl
prefLabel
A patient tumor transplant mod ...... tics in defined molecular bins
@en
A patient tumor transplant mod ...... ics in defined molecular bins.
@nl
P2093
P2860
P1433
P1476
A patient tumor transplant mod ...... tics in defined molecular bins
@en
P2093
Adrian Umpierrez
Aik-Choon Tan
Antonio Jimeno
Brian W Vogler
Daniel B Sehrt
Daniel W Bowles
David P Astling
David Raben
Diana F Hausman
Fred R Hirsch
P2860
P304
P356
10.1016/J.MOLONC.2013.03.004
P577
2013-04-04T00:00:00Z